Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.71 |
| ▸ | HPGD | P15428 | 3/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.65 |
| ▸ | RAB9A | P51151 | 2/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11238818 | 0.86 | HTT (0.56) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL1568297 | 0.86 | HTT (0.62) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL11391442 | 0.85 | ALOX5 (0.64) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL11248569 | 0.85 | HTT (0.60) | HTTHPGDALDH1A1POLBRAB9A | |
| Hydrochloric Acid SCHEMBL10926011 | 0.83 | ALOX5 (0.62) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL4552435 | 0.83 | HTT (0.55) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL7965188 | 0.83 | HTT (1.00) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL9692477 | 0.81 | CYP1A2 (0.63) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL11221273 | 0.80 | CA2 (0.56) | HTTHPGDALDH1A1POLBRAB9A | |
| SCHEMBL22393113 | 0.79 | HPGD (0.76) | HTTHPGDALDH1A1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8785474-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof to treat pain and other conditions | GRUENENTHAL GMBH (DE) | 2014-07-22 | — | — | US | disclosed |
| US-8084484-B2 | Vanilloid receptor ligands, pharmaceutical compositions containing them, process for making them, and use thereof for treating pain and other conditions | GRUENENTHAL GMBH (DE) | 2011-12-27 | — | — | US | disclosed |
| US-8084490-B2 | Sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | JANSSEN PHARMACEUTICA N.V. (BE) | 2011-12-27 | — | — | US | disclosed |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2011-12-08 | — | — | US | disclosed |
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | GRUENENTHAL GMBH (DE) | 2009-06-18 | — | — | US | disclosed |
| US-6486171-B2 | USEFUL IN THE TREATMENT OF SOME CENTRAL NERVOUS SYSTEM DISORDERS INCLUDING AS AN ANTIDEPRESSANT; 4-(1-(2-NAPHTHYL)ETHYL)-4- PIPERIDINYL)THIENO(3,2-C)PYRIDINE, FOR EXAMPLE | LES LABORATOIRES SERVIER (FR) | 2002-11-26 | — | — | US | disclosed |
| US-20020161228-A1 | Piperidine compounds | ADIR ET COMPAGNIE | 2002-10-31 | — | — | US | disclosed |
| US-6399616-B1 | 4-(4-(2-(5-(1,2,4-TRIAZOL-1-YLMETHYL)-1H-INDOL-3-YL)ETHYL)-1 -PIPERAZINYL)FURO(3,2-C)PYRIDINE; COMBINED SEROTONIN REUPTAKE INHIBITOR AND PARTIAL AGONIST OF 5-HT RECEPTORS; REDUCED LATENCY; DEPRESSION | LES LABORATOIRES SERVIER (FR) | 2002-06-04 | — | — | US | disclosed |
| CN-1083451-C | Process for synthesizing doxazosin mesylate | GUANGDONG KANGMEI HARMACEUTICA (CN) | 2002-04-24 | — | — | CN | disclosed |
| CN-1285353-A | Process for synthesizing doxazosin mesylate | GUANGDONG KANGMEI PHARMACEUTIC (CN) | 2001-02-28 | — | — | CN | disclosed |
| WO-1989006645-A1 | 1-AMINOMETHYL-1,2,3,4-TETRAHYDRONAPHTHALENES | ABBOTT LABORATORIES (US) | 1989-07-27 | — | — | WO | disclosed |
| US-4579845-A | Antihypertensive cyanoguanidines | BOUCHARA S.A. (FR) | 1986-04-01 | — | — | US | disclosed |
| US-4329348-A | ANTIDEPRESSANTS AND PSYCHOSTIMULANTS | CIBA-GEIGY CORPORATION (US) | 1982-05-11 | — | — | US | disclosed |
| EP-0004358-B1 | N-OXACYCLYLALKYL PIPERIDINES, PROCESS FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THESE COMPOUNDS | CIBA-GEIGY AG (CH) | 1982-01-06 | — | — | EP | disclosed |
| US-4301171-A | 2-(1,4-Benzodioxan-2-ylalkyl)benzimidazoles useful as anti-depressants | SYNTEX (U.S.A.) INC. (US) | 1981-11-17 | — | — | US | disclosed |
| EP-0004358-A1 | N-oxacyclylalkyl piperidines, process for their preparation, pharmaceutical compositions containing these compounds | CIBA-GEIGY AG (CH) | 1979-10-03 | — | — | EP | disclosed |
| US-4140781-A | Analgesic and neuraleptic 2-piperidinoalkyl-1,4-benzodioxans | CIBA-GEIGY CORPORATION (US) | 1979-02-20 | — | — | US | disclosed |
| US-4129655-A | Neuroleptic 2-piperidinoalkyl-1,4-benzodioxans | CIBA-GEIGY CORPORATION (US) | 1978-12-12 | — | — | US | disclosed |
| US-4104396-A | NEUROLEPTIC, ANALGESIC | CIBA-GEIGY CORPORATION (US) | 1978-08-01 | — | — | US | disclosed |
| US-4039676-A | NEUROLEPTIC AGENTS | CIBA-GEIGY CORPORATION (US) | 1977-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156590-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process for Making Them, and Use Thereof for Treating Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | HTT 3622/4885HPGD 366/4885ALDH1A1 1590/4885 |
| US-20110301156-A1 | Vanilloid Receptor Ligands, Pharmaceutical Compositions Containing Them, Process For Making Them, and Use Thereof to Treat Pain and Other Conditions | TRPV1, OPRL1, TRPV2 | HTT 3560/4885HPGD 378/4885ALDH1A1 1566/4885 |
| US-20020161228-A1 | Piperidine compounds | OTC, NPPA, AQP4 | HTT 1477/4885HPGD 568/4885ALDH1A1 673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.